2026-2034年全球酒精性肝炎治療市場規模、佔有率、趨勢和成長分析報告

預計酒精性肝炎治療市場規模將從 2025 年的 44 億美元成長到 2034 年的 83.1 億美元，並預計從 2026 年到 2034 年將以 7.32% 的複合年成長率成長。

由於與過度飲酒相關的肝病盛行率不斷上升，全球酒精性肝炎治療市場正在擴大。酒精性肝炎是嚴重的疾病，需要早期診斷和治療，因此對有效治療方法的需求日益成長。人們對肝臟健康的日益重視以及醫學研究的進步都促進了市場成長。

成長要素包括各地酒精消費量的增加、醫療保健支出的成長以及新治療方法的持續研究。目前的治療方法主要包括皮質類固醇、營養支持以及在重症病例中進行肝臟移植。此外，製藥公司正在投資開發標靶治療，以改善患者預後並降低死亡率。

未來，隨著創新藥物的問世和個人化治療方案的廣泛應用，市場預計將迎來顯著成長。生物技術的進步和對疾病機制的深入理解將有助於開發更有效的治療方法。人們對早期診斷和醫療保健日益成長的興趣也將進一步推動全球市場的發展。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球酒精性肝炎治療市場：依治療類別分類

• 市場分析、洞察與預測
• 皮質類固醇
• Pentoxifylline
• 抗氧化劑
• 營養補充品

第5章 全球酒精性肝炎治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈注射
• 皮下

第6章 全球酒精性肝炎治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 診所
• 居家照護

第7章 全球酒精性肝炎治療市場：依患者類型分類

• 市場分析、洞察與預測
• 成人
• 老年人
• 兒童

第8章 全球酒精性肝炎治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer
  • Amgen
  • Merck
  • Mylan
  • Eli Lilly
  • AbbVie
  • Takeda Pharmaceuticals
  • Roche
  • Johnson And Johnson
  • GlaxoSmithKline
  • Horizon Therapeutics
  • Novartis
  • BristolMyers Squibb
  • Gilead Sciences
  • Sanofi

The Alcoholic Hepatitis Therapeutics Market size is expected to reach USD 8.31 Billion in 2034 from USD 4.40 Billion (2025) growing at a CAGR of 7.32% during 2026-2034.

The global alcoholic hepatitis therapeutics market is expanding due to the rising prevalence of liver diseases associated with excessive alcohol consumption. Alcoholic hepatitis is a severe condition that requires timely diagnosis and treatment, leading to increased demand for effective therapeutic solutions. Growing awareness about liver health and advancements in medical research are contributing to market growth.

Major drivers include increasing alcohol consumption in various regions, rising healthcare expenditure, and ongoing research into novel treatment options. Current therapies focus on corticosteroids, nutritional support, and liver transplantation in severe cases. Additionally, pharmaceutical companies are investing in the development of targeted therapies to improve patient outcomes and reduce mortality rates.

In the future, the market is expected to witness significant growth with the introduction of innovative drugs and personalized treatment approaches. Advances in biotechnology and a better understanding of disease mechanisms will support the development of more effective therapies. Increasing focus on early diagnosis and preventive healthcare will further drive market expansion globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Category

• Corticosteroids
• Pentoxifylline
• Antioxidants
• Nutritional Supplements

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By End User

• Hospitals
• Clinics
• Homecare

By Patient Type

• Adult
• Geriatric
• Pediatric

COMPANIES PROFILED

• Pfizer, Amgen, Merck, Mylan, Eli Lilly, AbbVie, Takeda Pharmaceuticals, Roche, Johnson and Johnson, GlaxoSmithKline, Horizon Therapeutics, Novartis, BristolMyers Squibb, Gilead Sciences, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ALCOHOLIC HEPATITIS THERAPEUTICS MARKET: BY THERAPEUTIC CATEGORY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Category
• 4.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pentoxifylline Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antioxidants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nutritional Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ALCOHOLIC HEPATITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ALCOHOLIC HEPATITIS THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ALCOHOLIC HEPATITIS THERAPEUTICS MARKET: BY PATIENT TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Patient Type
• 7.2. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ALCOHOLIC HEPATITIS THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapeutic Category
  • 8.2.2 By Route Of Administration
  • 8.2.3 By End User
  • 8.2.4 By Patient Type
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapeutic Category
  • 8.3.2 By Route Of Administration
  • 8.3.3 By End User
  • 8.3.4 By Patient Type
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapeutic Category
  • 8.4.2 By Route Of Administration
  • 8.4.3 By End User
  • 8.4.4 By Patient Type
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapeutic Category
  • 8.5.2 By Route Of Administration
  • 8.5.3 By End User
  • 8.5.4 By Patient Type
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapeutic Category
  • 8.6.2 By Route Of Administration
  • 8.6.3 By End User
  • 8.6.4 By Patient Type
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ALCOHOLIC HEPATITIS THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer
  • 10.2.2 Amgen
  • 10.2.3 Merck
  • 10.2.4 Mylan
  • 10.2.5 Eli Lilly
  • 10.2.6 AbbVie
  • 10.2.7 Takeda Pharmaceuticals
  • 10.2.8 Roche
  • 10.2.9 Johnson And Johnson
  • 10.2.10 GlaxoSmithKline
  • 10.2.11 Horizon Therapeutics
  • 10.2.12 Novartis
  • 10.2.13 BristolMyers Squibb
  • 10.2.14 Gilead Sciences
  • 10.2.15 Sanofi